Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Pius Maliakal"'
Autor:
Lan Gao, Diksha Kaushik, Brian A. Van Tine, Matthew A. Ingham, Steven Attia, Christian F. Meyer, Gary K. Schwartz, Pius Maliakal, John D. Baird, Jiyuan Ma, Rosemary Barrett, Dhiren D'Silva, Kylie O'Keefe, Ronald Kong
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 2, Pp n/a-n/a (2024)
Abstract Unesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive surro
Externí odkaz:
https://doaj.org/article/67669181c17b40ddb322ddfc3dd1c1a1
Autor:
William A. Wegener, David M. Goldenberg, RL Moroose, Joyce O'Shaughnessy, Dejan Juric, Aditya Bardia, Sara M. Tolaney, Jennifer R. Diamond, Vandana G. Abramson, Ingrid A. Mayer, Pius Maliakal, Linda T. Vahdat, T. Goswami, Kevin Kalinsky, Robert M. Sharkey, Q. Hong
Publikováno v:
Ann Oncol
Background Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC). Sacituzumab govitecan (SG; Trodelvy®) is an antibody–drug conjugate composed of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aca34a7b5e23ab7f22ceead5802a363a
https://doi.org/10.1016/j.annonc.2020.09.004
https://doi.org/10.1016/j.annonc.2020.09.004
Autor:
Brian Andrew Van Tine, Matthew Ingham, Steven Attia, Christian Frederick Meyer, John Baird, Dhiren D'Silva, Kylie O'Keefe, Pius Maliakal, Mona M. Wahba, Marla Weetall, Gary K. Schwartz
Publikováno v:
Journal of Clinical Oncology. 40:11507-11507
11507 Background: Leiomyosarcoma (LMS) is one of the most common subtypes of soft tissue sarcoma and is associated with high risk of relapse and a poor prognosis for advanced disease. In preclinical LMS models, unesbulin, a microtubule polymerization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f523fd5e6e9b50f0e3ee57a69a79d4e4
https://doi.org/10.1200/jco.2022.40.16_suppl.11507
https://doi.org/10.1200/jco.2022.40.16_suppl.11507
Autor:
Jordan Berlin, Takefumi Komiya, Gregory A. Masters, J.M. Lang, Linda T. Vahdat, RL Moroose, E.A. Kio, Kevin Kalinsky, Robert M. Sharkey, Jenny C. Chang, T. Goswami, Vincent J. Picozzi, William A. Wegener, Joyce O'Shaughnessy, Alessandro D. Santin, Alexander Starodub, Q. Hong, Wells A. Messersmith, Allyson J. Ocean, David M. Goldenberg, Jhanelle E. Gray, Pius Maliakal, Aditya Bardia
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(6)
Background Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter trial (NCT01631552) in patients with ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c67cb35ea061782f38436eee87225cb1
https://pubmed.ncbi.nlm.nih.gov/33741442
https://pubmed.ncbi.nlm.nih.gov/33741442
Autor:
Sara M. Tolaney, Jennifer R. Diamond, Linda T. Vahdat, Aditya Bardia, IA Mayer, DM Goldenberg, Pius Maliakal, William A. Wegener, Kevin Kalinsky, SJ Isakoff, Alessandro D. Santin, N. Shah, Joyce A. O'Shaughnessy, Vandana G. Abramson, RL Moroose, Robert M. Sharkey, Serengulam V. Govindan
Publikováno v:
Cancer Research. 78:P1-12
This abstract was withdrawn by the authors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eed7bab0085a6c89a192c0c9c344e92e
https://doi.org/10.1158/1538-7445.sabcs17-p1-12-01
https://doi.org/10.1158/1538-7445.sabcs17-p1-12-01
Autor:
Linda T. Vahdat, IA Mayer, Alessandro D. Santin, Sara M. Tolaney, RL Moroose, Jennifer R. Diamond, DM Goldenberg, Pius Maliakal, N. Shah, Kevin Kalinsky, Robert M. Sharkey, Joyce A. O'Shaughnessy, SJ Isakoff, William A. Wegener, Serengulam V. Govindan, Aditya Bardia, Vandana G. Abramson
Publikováno v:
Cancer Research. 78:GS1-07
Background: mTNBC has an aggressive course with limited therapeutic options. Sacituzumab govitecan (IMMU-132) is a novel antibody drug conjugate consisting of SN-38, the active metabolite of the topoisomerase I inhibitor, irinotecan, conjugated to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7029bc8324b01dd0964b413ec6b41d64
https://doi.org/10.1158/1538-7445.sabcs17-gs1-07
https://doi.org/10.1158/1538-7445.sabcs17-gs1-07
Autor:
Natasha Pillay Smiley, John C. Breneman, Charles B. Stevenson, Eugene Hwang, Shiva Senthil Kumar, Patricia Baxter, Adam Lane, Xiao-Nan Li, Renee Doughman, Pius Maliakal, Maryam Fouladi, Clinton F. Stewart, Michelle Deutsch, Jim Leach, Sonia Romero, Rachid Drissi, Lan Gao
Publikováno v:
Neuro-Oncology
BACKGROUND BMI-1 is highly expressed in DIPG. Downregulation leads to inhibition of cell proliferation, cell cycle signaling, self-renewal, telomerase expression, activity, and suppression of DIPG cell migration. Targeted inhibition of BMI-1 sensitiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eca15cf11edcc2e6ba12d2533a4aa1ed
https://doi.org/10.1093/neuonc/noaa222.138
https://doi.org/10.1093/neuonc/noaa222.138
Autor:
Allyson J. Ocean, David M. Goldenberg, Pius Maliakal, Michael J. Guarino, William A. Wegener, Kevin Kalinsky, Alexander Starodub, D. Ross Camidge, Jamal Misleh, Wells A. Messersmith, Boyd Mudenda, Robert M. Sharkey, Jhanelle E. Gray, Ebenezer A. Kio, Leena Gandhi, Tirrell Johnson, Gregory A. Masters, Bryan J. Schneider, Rebecca S. Heist, Charles J. Schneider, Ronald J. Scheff, W. Thomas Purcell, Serengulam V. Govindan
Publikováno v:
Clinical Cancer Research. 23:5711-5719
Purpose: We evaluated a Trop-2–targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients. Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1–7) mSCLC who re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e3588f6c198004cae5f52ab2059f6c0
https://doi.org/10.1158/1078-0432.ccr-17-0933
https://doi.org/10.1158/1078-0432.ccr-17-0933
Autor:
Linda T. Vahdat, Aditya Bardia, Alexander Starodub, William A. Wegener, Steven J. Isakoff, Allyson J. Ocean, David M. Goldenberg, Sara M. Tolaney, Robert M. Sharkey, Nikita C. Shah, Jennifer R. Diamond, Ingrid A. Mayer, Pius Maliakal, Dejan Juric, Joyce O'Shaughnessy, Vandana Abramson, Wells A. Messersmith, Michael J. Guarino, Rebecca L. Moroose, Serengulam V. Govindan, Kevin Kalinsky, Jordan Berlin
Publikováno v:
Journal of Clinical Oncology. 2017:2141-2148
Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb8878d0224a3477e09132be0a1092b
https://doi.org/10.1200/jco.2016.70.8297.2017.2.test
https://doi.org/10.1200/jco.2016.70.8297.2017.2.test
Autor:
Steven J. Isakoff, Aditya Bardia, William A. Wegener, Pius Maliakal, Wells A. Messersmith, Linda T. Vahdat, Ingrid A. Mayer, Alexander Starodub, Robert M. Sharkey, Michael J. Guarino, Allyson J. Ocean, Vincent J. Picozzi, Serengulam V. Govindan, David M. Goldenberg
Publikováno v:
Cancer. 123:3843-3854
BACKGROUND Sacituzumab govitecan (IMMU-132), an antitrophoblastic cell-surface antigen (anti-Trop-2) humanized antibody-SN-38 conjugate, had encouraging efficacy in the phase 1 clinical trial. This report further examines the pharmacokinetics and saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8620318bf8d6223328f213601963166c
https://doi.org/10.1002/cncr.30789
https://doi.org/10.1002/cncr.30789